Article
Is there evidence for the use of FLT3 inhibitors as maintenance therapy in AML?
Best practice & research. Clinical haematology - 1 Mar 2021
Levis Mark
Abstract excerpt
It is often assumed that all patients with FLT3 (FMS-Like Tyrosine kinase-3)-mutated AML who undergo an allogeneic transplant should receive maintenance therapy with a FLT3 inhibitor. The validity of this assumption is controversial.
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
